Table 3.
Optimal MS/MS conditions and quantitation limits for analyzed compounds.
| Compound | Precursor Ion (m/z) |
Product Ion 1 (m/z) |
Product Ion 2 (m/z) |
Fragmentor Voltage |
Collision Energy |
Polarity | Limit of Detection* (ng/mL) |
Limit of Quantitation * (ng/mL) |
|---|---|---|---|---|---|---|---|---|
| Acetylsalicylic Acid | 179.1 | 137 | 93 | 50 | 4 | − | 100 | 250 |
| Aliskiren | 552.8 | 436.3 | 418.2 | 155 | 13 | + | 0.5 | 1 |
| Amlodipine | 409.2 | 294.1 | 238.2 | 90 | 9 | + | 0.25 | 0.5 |
| Atenolol | 267.2 | 190.1 | 145.1 | 116 | 14 | + | 1 | 10 |
| Atorvastatin | 559.6 | 440.2 | 250.1 | 140 | 20 | + | 0.1 | 0.25 |
| Canrenone (Spironolactone) | 341.2 | 107.1 | 91.1 | 148 | 30 | + | 2.5 | 5 |
| Captopril | 218.3 | 116.1 | 70.1 | 80 | 9 | + | 500 | NQ |
| Carvedilol | 407.5 | 222.1 | 100.1 | 140 | 24 | + | 0.5 | 1 |
| Clonidine | 230.2 | 160 | 44.2 | 148 | 38 | + | 0.2 | 1 |
| Clopidogrel | 322.8 | 184 | 155 | 110 | 20 | + | 1 | 5 |
| Digoxin | 651.3 | 131.1 | 97.1 | 160 | 21 | + | 0.25 | 1 |
| Diltiazem | 415.3 | 178 | 150 | 140 | 21 | + | 0.5 | 1 |
| Enalapril | 377.2 | 234.1 | 91.1 | 116 | 14 | + | 0.25 | 1 |
| Enalaprilat | 349.4 | 206 | 117 | 120 | 13 | + | 1 | 1 |
| Fenofibrate | 361.1 | 233 | 139 | 130 | 13 | + | 5 | 100 |
| Fenofibric Acid | 319.08 | 233 | 139 | 110 | 13 | + | 5 | 250 |
| Furosemide | 329.3 | 285 | 204.9 | 110 | 9 | + | 5 | 12.5 |
| Hydrochlorothiazide | 296.2 | 268.9 | 204.9 | 140 | 13 | + | 5 | 5 |
| Hydralazine | 161.1 | 89.1 | 63.1 | 100 | 22 | + | 5 | 25 |
| Isosorbide | 147.1 | 88.1 | 69.1 | 50 | 5 | + | 10 | NQ |
| Lisinopril | 406.2 | 246.1 | 84.1 | 132 | 22 | + | 1 | 5 |
| Losartan | 423.2 | 207.1 | 180 | 116 | 22 | + | 0.1 | 0.5 |
| Lovastatin | 405.6 | 225.2 | 199.2 | 80 | 13 | + | 2 | 5 |
| Methyldopa | 212.2 | 166.1 | 139 | 80 | 12 | + | 100 | 500 |
| Metoprolol | 268.3 | 133.1 | 116.1 | 116 | 26 | + | 0.25 | 1 |
| Metoprolol acid | 268.3 | 133.1 | 116.1 | 116 | 26 | + | ** | NQ |
| Niacin | 124.1 | 80.1 | 78.1 | 110 | 21 | + | NQ | NQ |
| Nifedipine | 347.3 | 315.1 | 194.1 | 80 | 5 | + | 1 | 1 |
| Pravastatin | 423.5 | 321.2 | 101.1 | 140 | 9 | − | 2 | 10 |
| Propranolol | 260.4 | 116.1 | 56.2 | 110 | 16 | + | 0.5 | 1 |
| Ramipril | 417.3 | 234.1 | 117.1 | 140 | 17 | + | 0.2 | 1 |
| Ramiprilat | 389.3 | 206.2 | 156.2 | 140 | 17 | + | ** | ** |
| Salicylic acid | 137.1 | 93 | 65.1 | 80 | 12 | − | 50 | 250 |
| Simvastatin | 419.6 | 285.1 | 225.1 | 80 | 4 | + | 0.5 | 1 |
| Simvastatin | 419.6 | 199.1 | 80 | 4 | + | 0.5 | 1 | |
| Sulfameter (IS) | 281.3 | 108.1 | 92.1 | 110 | 25 | + | N/A | N/A |
| Sulfameter (IS) | 279.3 | 264 | 196 | 110 | 5 | − | N/A | N/A |
| Telmisartan | 515.2 | 497.3 | 276.1 | 160 | 40 | + | 0.2 | 1 |
| Triamterene | 254.3 | 237.1 | 104.1 | 165 | 25 | + | 0.2 | 0.2 |
| Valsartan | 436.2 | 291.1 | 207.1 | 100 | 14 | + | 0.5 | 10 |
| Verapamil | 455.2 | 165.1 | 150.1 | 164 | 26 | + | 0.2 | 1 |
| Warfarin | 309.3 | 251.1 | 163 | 110 | 17 | + | 0.2 | 100 |
*
Where significant interference prevented quantification below a set LOD, LOD and LOQ are identical
**
when the authenticated standard was unavailable, we used the estimated metabolite mass, parameters of the parent compound, and fragment ion based on literature review
Abbreviation: LOD, limit of detection; LOQ, limit of quantitation; N/A, not applicable; NQ, not quantifiable